Research Analysts Set Expectations for HALO FY2026 Earnings

Key Points

• Leerink Partners raised their FY2026 earnings estimate for Halozyme Therapeutics to $8.18 per share, slightly up from a previous estimate of $8.11, while the current consensus for FY2025 is $4.73 per share.
• Halozyme posted an earnings report for the last quarter with an EPS of $1.54, surpassing estimates significantly and marking a 40.8% increase in revenue year-over-year.
• Insider transactions show significant stock sales by top executives, with CFO Nancy Labrosse selling 20,000 shares and experiencing a 45.14% decrease in their ownership, reflecting potential concerns about future performance.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2026 earnings per share estimates for shares of Halozyme Therapeutics in a research note issued on Wednesday, October 1st. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $8.18 per share for the year, up from their prior forecast of $8.11. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $4.73 per share.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. During the same period last year, the company earned $0.91 earnings per share. The business's quarterly revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS.

Other research analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. Benchmark boosted their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a research note on Wednesday, September 24th. JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. The Goldman Sachs Group began coverage on Halozyme Therapeutics in a report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 target price for the company. Finally, HC Wainwright increased their price target on Halozyme Therapeutics from $85.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $70.44.

Halozyme Therapeutics Trading Down 4.3%

HALO opened at $71.69 on Friday. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. Halozyme Therapeutics has a fifty-two week low of $42.01 and a fifty-two week high of $79.50. The company's 50 day moving average price is $70.23 and its two-hundred day moving average price is $61.92. The firm has a market capitalization of $8.39 billion, a price-to-earnings ratio of 16.41, a PEG ratio of 0.41 and a beta of 1.16.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 20,000 shares of the firm's stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total value of $1,514,200.00. Following the transaction, the chief financial officer directly owned 24,306 shares of the company's stock, valued at approximately $1,840,207.26. This trade represents a 45.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bernadette Connaughton sold 4,000 shares of the business's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total transaction of $294,720.00. Following the sale, the director directly owned 46,952 shares of the company's stock, valued at approximately $3,459,423.36. The trade was a 7.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 88,227 shares of company stock worth $6,020,595. Insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. DLD Asset Management LP bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth $650,250,000. Arrowstreet Capital Limited Partnership grew its position in Halozyme Therapeutics by 127.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company's stock valued at $132,192,000 after buying an additional 1,425,674 shares during the period. Qube Research & Technologies Ltd purchased a new stake in Halozyme Therapeutics during the second quarter worth about $51,295,000. Los Angeles Capital Management LLC raised its position in Halozyme Therapeutics by 951.8% in the second quarter. Los Angeles Capital Management LLC now owns 973,670 shares of the biopharmaceutical company's stock worth $50,650,000 after acquiring an additional 881,094 shares during the period. Finally, Norges Bank purchased a new position in Halozyme Therapeutics in the second quarter valued at about $45,027,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.